Access status · registered as it stands
BPC-157 Legal Status, FDA 503A Category, and Compounding Access
Two facts, kept distinct: access is under active FDA review and may expand in 2026 — and as of today BPC-157 sits in FDA 503A Category 2. A scheduled evaluation is not a decision.
Why the BPC-157 legal status is moving
The BPC-157 legal status is worth reading closely right now because the access picture is in motion. BPC-157 is individually named on the published agenda of the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23-24, 2026, as a bulk drug substance "being considered for inclusion on the 503A Bulks List" — the same agenda that also lists KPV, TB-500, and MOTs-C [18]. That is real, scheduled, FDA-calendar momentum: access is under active FDA review and may expand in 2026.
What that agenda item is not, however, is a decision. Being placed on a PCAC agenda is a step in evaluation, not a listing, not a reclassification, and not a change in current status. The committee discusses; FDA decides separately, later, by rulemaking. So the rest of this page keeps the forward-leaning fact and the present-tense fact in separate columns, and never lets the scheduled discussion stand in for an outcome that has not happened.
This page is general information about the regulatory landscape. It is not medical or legal advice, and it is not an offer to sell or supply any substance.
The current FDA fact, stated present-tense
As of today, BPC-157 — evaluated by FDA under the entries "BPC-157 (free base)" and "BPC-157 acetate" — is a research peptide that FDA placed in 503A Category 2: bulk substances that may present significant safety risks. The placement is effective with FDA's September 29, 2023 update to the list of bulk drug substances nominated for use under section 503A, and FDA cited concerns including potential immunogenicity for certain routes of administration and complexities with peptide-related impurities and active-ingredient characterization [16].
Two consequences follow directly, and both are present-tense facts. First, as a Category 2 substance, BPC-157 is not within FDA's enforcement-discretion policy for 503A compounding. Second, BPC-157 is not an FDA-approved drug — approval of a finished drug is a separate question from whether a bulk substance may be used in compounding, and BPC-157 has neither status [16].
Nothing here states or implies any reclassification as already done, dated, or certain. Reports circulating in early 2026 of peptides moving back toward Category 1, or of BPC-157 being "removed" from Category 2 on a specific date, could not be confirmed from an authoritative FDA source and are not treated as fact on this page. The last FDA action confirmable from FDA.gov is the Category 2 placement, and that is what is stated.
How the 503A and 503B framework works
Under the Federal Food, Drug, and Cosmetic Act, two sections govern compounding. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies, federal facilities, and licensed physicians, generally pursuant to a valid prescription for an individual patient. Section 503B covers FDA-registered outsourcing facilities that compound larger batches under cGMP-style oversight and FDA registration and inspection [17].
A compounder may use a bulk drug substance — an active ingredient used as a starting material, rather than an FDA-approved finished drug — only if that substance has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the relevant FDA bulks list. Substances not yet on a bulks list are evaluated through a public nomination process with input from the PCAC [17].
FDA's earlier interim policy sorted nominated substances into Category 1 (covered by enforcement discretion while under evaluation) and Category 2 (identified as raising significant safety risks; not covered). On January 7, 2025, FDA finalized a revised interim policy under which it no longer places newly nominated substances into these numbered categories; substances already in Category 1 may continue within the interim discretion, while substances in Category 2 are not afforded that discretion even with updated nominations [17]. BPC-157 stands in Category 2 [16].
What this means for compounded access
Legally compounded peptide access follows one pathway, and it is the same regardless of the substance. A patient is evaluated by an appropriately licensed prescriber — in person or through a compliant telehealth encounter — who determines whether a compounded preparation is clinically appropriate. If it is appropriate and lawful, the prescriber issues a valid, patient-specific prescription. The preparation is then made by a state-licensed 503A compounding pharmacy (patient-specific) or, for office or batch use, sourced from an FDA-registered 503B outsourcing facility [17].
Telehealth is a front-end channel for the prescriber-evaluation step, not a separate legal status: it does not expand which substances may be compounded and does not remove the need for a legitimate clinical evaluation and a valid prescription [17].
The ingredient-eligibility caveat is the part that matters most here. A compounder may use a requested active ingredient only if that ingredient is eligible under the 503A and 503B bulk-substance rules — and a Category 2 substance that FDA has flagged for significant safety risks is not eligible for routine 503A compounding while that status stands [16]. That is the current constraint on BPC-157. The July 2026 PCAC discussion [18] may change the evaluation, but it has not yet, and this page does not assume an outcome. This is general information, not medical or legal advice, and not an offer to sell or supply BPC-157 or any substance.